Guangzhou Innogen Pharmaceutical Group (2591) H1 2025 earnings summary

Executive summary

• Efsubaglutide Alfa received China approval for type 2 diabetes in January 2025 and launched in February, generating RMB56.4 million in H1 revenue.

• H1 net loss widened to RMB122.5 million from RMB75.3 million as R&D and selling costs rose with pipeline development and commercialization.

• H shares listed on 15 August 2025; the global offering generated HK$634.7 million in net proceeds.

Financial highlights

• Revenue was RMB56.4 million, primarily from Efsubaglutide Alfa sales in China; cost of sales was RMB6.0 million.

• Gross profit was RMB50.5 million and gross margin 89.4%; pre-commercial manufacturing costs were recorded as R&D expenses.

• R&D expenses rose to RMB99.1 million from RMB51.9 million, driven by process improvements, raw materials and obesity-trial spending.

• Selling and distribution expenses were RMB44.0 million versus nil, reflecting launch marketing and commercialization-team expansion; administrative expenses were RMB31.6 million versus RMB30.1 million.

• Net loss was RMB122.5 million versus RMB75.3 million; basic and diluted loss per share was RMB0.29 versus RMB0.18.

Outlook and guidance

• H2 2025 priorities include global T2D expansion, advancing obesity and overweight trials, and continuing NRDL efforts.

• China Phase IIb/III obesity and overweight trial, initiated in March 2025, is expected to complete in Q4 2026; the Australia Phase II trial began enrolling in August 2025, with ~200 subjects expected.

• A Southeast Asian T2D BLA was submitted in June 2025; a Latin American BLA is planned for H2 2025, with further overseas applications subject to local review and possible requests for additional trials.

• A multi-center Phase IIa MASH trial in China and the U.S. is planned for 2026; NMPA and FDA IND approvals have been granted.

• IND submissions are planned for YN014 in H1 2026 and YN401, YN209, YN203 and YN202 during 2025–2026.